{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:23:24Z","timestamp":1791944604787,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101712","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T04:56:56Z","timestamp":1665550616000},"page":"101712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immunotherapy in pituitary carcinomas and aggressive pituitary tumors"],"prefix":"10.1016","volume":"36","author":[{"given":"G\u00e9rald","family":"Raverot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela Diana","family":"Ilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101712_bib1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101712_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2022.101712_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ecl.2020.05.008","article-title":"Aggressive pituitary adenomas and carcinomas","volume":"49","author":"Ilie","year":"2020","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.beem.2022.101712_bib4","first-page":"1","article-title":"Emerging and novel treatments for pituitary tumors","volume":"8","author":"Ilie","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.beem.2022.101712_bib5","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A\u00a0decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2022.101712_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101712_bib7","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.beem.2022.101712_bib8","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101712_bib9","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.beem.2022.101712_bib10","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?","volume":"184","author":"Sol","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101712_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.beem.2022.101712_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.576027","article-title":"Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101712_bib13","doi-asserted-by":"crossref","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2022.101712_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J\u00a0Personalized Med"},{"key":"10.1016\/j.beem.2022.101712_bib15","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","author":"Goichot","year":"2021","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101712_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/ERC-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review","volume":"29","author":"Ilie","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101712_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.13365","article-title":"The adverse events associated with combination immunotherapy in cancers: challenges and chances","volume":"16","author":"Zhuo","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.beem.2022.101712_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12022-021-09673-2","article-title":"PD-L1 is preferentially expressed in PIT-1 positive pituitary neuroendocrine tumours","volume":"32","author":"Turchini","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2022.101712_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response rates to anti\u2013PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2022.101712_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: main achievements and challenges","volume":"18","author":"Varad\u00e9","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.beem.2022.101712_bib21","article-title":"Clinical relevance of tumour-associated macrophages","author":"Pittet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beem.2022.101712_bib22","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa520","article-title":"Immune landscape of pituitary neuroendocrine tumours reveals association between macrophages and gonadotroph-tumour invasion","author":"Principe","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101712_bib23","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1038\/s41388-019-0779-5","article-title":"Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors","volume":"38","author":"Barry","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2022.101712_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0830-3","article-title":"Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours","volume":"7","author":"Marques","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/j.beem.2022.101712_bib25","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.7150\/thno.53749","article-title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.beem.2022.101712_bib26","first-page":"1","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.beem.2022.101712_bib27","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.18632\/oncotarget.26775","article-title":"Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes","volume":"10","author":"Yagnik","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2022.101712_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2022.101712_bib29","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2022.101712_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1210\/jc.2009-1583","article-title":"Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma","volume":"95","author":"Lupi","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101712_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01114-3","article-title":"Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression","volume":"24","author":"Mei","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101712_bib32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12020-019-02145-y","article-title":"Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours","volume":"67","author":"Iacovazzo","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101712_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00441-016-2564-x","article-title":"Identification of M2 macrophages in anterior pituitary glands of normal rats and rats with estrogen-induced prolactinoma","volume":"368","author":"Fujiwara","year":"2017","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.beem.2022.101712_bib34","doi-asserted-by":"crossref","first-page":"dgaa497","DOI":"10.1210\/clinem\/dgaa497","article-title":"Treatment options for gonadotroph tumors: current state and perspectives","volume":"105","author":"Ilie","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101712_bib35","doi-asserted-by":"crossref","first-page":"e3207","DOI":"10.1210\/clinem\/dgaa449","article-title":"The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness","volume":"105","author":"Wang","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:30Z","timestamp":1761497910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22000999"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101712","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in pituitary carcinomas and aggressive pituitary tumors","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101712"}}